Transform lab productivity, save analyst time
 |
 |
Fast development - new assays can be running within days |
|
|
Fast assay turnaround - automation improves throughput, speeds up validation |
|
|
Fewer dilutions - broad dynamic range and reduced matrix effects |
|
|
Multiple analytes measured in limited sample volumes – low sample consumption |
Transfer easily between labs or into regulated environments
|
|
Template methods simplify outsourcing and assay transfer |
|
|
Gyrolab software is 21 CFR Part 11 compliant and regulatory support is available |
Data examples
Development of an hIL-8 cytokine assay
Quotient Bioresearch is a contract research organization that was looking for an improved alternative to the ELISA kit they were using for an hIL-8 biomarker assay. By transferring to the Gyros immunoassay platform they were able to:
|
|
Reduce assay time from four hours to less than one hour |
|
|
Increase dynamic range 10-fold |
|
|
Reduce sample consumption 10-fold |
Today, working in a GxP environment, the company uses the Gyros platform for routine PK and PD analysis of proteins in different matrices.
Increased dynamic range and sensitivity
Gyrolab workstation, using a Bioaffy 200 CD. Data presented at Gyrolab Seminars 2009
Excellent accuracy and precision
Gyrolab workstation – QC samples in plasma diluted 1:1 in Rexxip H-max (%RE: % recovery error).Data presented at Gyrolab Seminars 2009
Saved sample and time
Gyrolab workstation, using a Bioaffy 200 CD. Data presented at Gyrolab Seminars 2009
Data courtesy of A. Roberts, Quotient Bioresearch.
For more details, listen to Dr. Roberts’ presentation ‘PK and PD analysis of proteins in different matrices using Gyrolab’, Gyrolab Seminar 2009
Validation of an Abeta cytokine assay in CSF
ICON Development Solutions is a contract research organization that wanted to determine if using the Gyros immunoassay platform would overcome limitations of an established ligand-binding assay used to quantify the biomarker amyloid beta (Abeta). The manual ligand-binding assay had a 3-day run time, run at relatively high cost, and could only be performed in small batches due to problems with edge effects. Availability of antibody and sample were also limiting factors. By transferring to the Gyros immunoassay platform they were able to:
|
|
Achieve comparable performance with increased cost-effectiveness |
|
|
Reduce assay time from 3 days to 1.5 hours |
|
|
Reduce interference from matrix effects and achieve a broader dynamic range |
|
|
Reduce sample and antibody consumption |
Today, ICON Development uses the Gyros platform for biomarker, PK, and immunogenicity studies.
Excellent dynamic range – up to 16000 pg/ml.
Data presented at Gyrolab Seminars 2009
No matrix effects – strong parallelism
Data presented at Gyrolab Seminars 2009
Data courtesy of J. Chappell, ICON.
For more details, listen to Dr. Chappell’s presentation ‘Use of Gyrolab in a Contract Research Environment’, Gyrolab Seminar 2009
Biomarkers analyzed successfully on the Gyros platform include:
Human | |||
|
|
hAmyloid beta 1-40, hAmyloid beta 1-42, hAmyloid beta total hIL-10, hIL-12 p70, hGM-CSF hIFN-γ hIgG hInsulin hIP10/CXCL10 hMCP-1 hMIP-1α, hMIP-1β hMMP-3 hNGF hPlGF hTau (total), hTau (phospho) T181 hTissue Factor hTNF-α, hTNF-β hTSH hVEGF |
|
Mouse | |||
|
|
mAdiponectin mGM-CSF mIFN-γ mIgG mIL-10, mIL-12a, mLipocalin mInsulin mTNF-α |
|
Rat | |||
|
|
rAbeta 1-40 rAbeta 1-42 rInsulin |
|
All assays performed in-house or at customer sites using commercially-available reagents